humAIn: Emotional Engineering for Adherence
We detect early signals of therapeutic bond breakdown and turn emotion into actionable intervention.
- Emotional dropout risk by cohort, treatment, and country.
- Predictive window: “without intervention, dropout occurs in X weeks.”
- Recommended tone, channel, and timing.
Not a clinical decision system. A strategic emotional-risk layer based on real-world signals.
Non-adherence has become a structural cost
Globally, medication non-adherence is associated with massive unrealized revenue, estimated in the hundreds of billions of USD per year.
In chronic therapies, a significant portion of patients discontinue. Beyond pharmacology, a meaningful share is driven by emotional and cognitive factors—fear, denial, therapeutic fatigue, distrust, and subjective risk/benefit perception.
30%–50%: chronic therapy dropout (reference range).
Early critical window: first weeks are decisive for persistence.
An emotional decision infrastructure
humAIn uses multi-level emotional analysis to anticipate when a dominant emotion blocks therapeutic action—before it becomes discontinuation.
Detect the effective emotion (not just surface sentiment).
Map it to the functional triad: instinctive, socio-emotional, analytical.
Recommend minimal intervention: tone, timing, channel.
What your team gets
Emotional Adherence Risk Score (0–100) by cohort/treatment/country.
Emotional Friction Map: where the bond breaks (by stage and channel).
Predictive Dropout Window: time estimate to dropout without intervention.
Recommended interventions: message type, tone, timing, channel.
Typical use cases
Case 01
Patient support programs: prioritize follow-up where emotional risk rises.
Case 02
Medical Affairs / Patient Experience: redesign journeys with emotional evidence.
Case 03
Pharmacy / operational adherence: trigger proactive contact during the early window.
Turn emotional risk into preventive action
In minutes, see where dropout is forming and what minimal intervention to apply.